dziennika egzotyczny pieścić medycyny centrum medyczne zdrowie Denver

Zgoda On Roy, Gelabale, Johnson, Trades, Kahn

Jerry Zgoda of The Star Tribune opined that Brandon Roy's current rehab treatment could be a way for the Timberwolves to bide time in case they need his $5MM contract in a trade near the deadline, noting that it couldn't be used in a deal if he were to retire. In the rest of tonight's column, Zgoda addressed a few more hot topics that have been brewing in Minnesota:

  • He also clarifies that if the team wants to keep both Mickael Gelabale and Chris Johnson, they'd have to find a way to free up a roster spot as a player can only sign two 10-day contracts before his next deal becomes fully guaranteed. Dealing Louis Amundson for a future draft pick or waiving a player could also be considered. 
  • On the trade front, he identifies Derrick Williams as the best piece they can offer in a meaningful deal by the trade deadline unless they deem Nikola Pekovic expendable. 
  • To expand on Pekovic, Zgoda notes that the Montenegrin center is set to hit the free agent market this summer and could be dealt by the deadline or in an offseason sign-and-trade if management doesn't want to commit to the $12MM-$14MM that he could command on the free agent market. 
  • With this season being GM David Kahn's final of a four year deal, Zgoda wonders if Kahn will be considered the right fit to continue to lead the front office. 
  • Rick Adelman's return to the team is dependent on the continued improvement of his wife's health, which could allow him to rejoin the team as soon as this Wednesday. 


newest oldest

One thought on “Zgoda On Roy, Gelabale, Johnson, Trades, Kahn

  1. Sky14

    I hope the Wolves let Kahn go this offseason, his track record drafting has been horrible.

Leave a Reply

Your email address will not be published. Required fields are marked *

 Notify me of followup comments via e-mail.

You can click here to Subscribe without commenting

Get the hottest NBA news and rumors before anyone else! Follow us on Twitter to stay updated: